Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 6
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. Sadrkhanloo M, et al. Among authors: hejazi es. Pharmacol Res. 2022 Aug;182:106311. doi: 10.1016/j.phrs.2022.106311. Epub 2022 Jun 15. Pharmacol Res. 2022. PMID: 35716914 Review.
Targeting PI3K/Akt signaling in prostate cancer therapy.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: hejazi es. J Cell Commun Signal. 2022 Nov 11. doi: 10.1007/s12079-022-00702-1. Online ahead of print. J Cell Commun Signal. 2022. PMID: 36367667 Review.
SOX2 function in cancers: Association with growth, invasion, stemness and therapy response.
Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, Rezaei S, Hejazi ES, Kakavand A, Heidari H, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Among authors: hejazi es. Biomed Pharmacother. 2022 Dec;156:113860. doi: 10.1016/j.biopha.2022.113860. Epub 2022 Oct 20. Biomed Pharmacother. 2022. PMID: 36272267 Free article. Review.
siRNA and targeted delivery systems in breast cancer therapy.
Mirzaei S, Paskeh MDA, Entezari M, Bidooki SH, Ghaleh VJ, Rezaei S, Hejazi ES, Kakavand A, Behroozaghdam M, Movafagh A, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Among authors: hejazi es. Clin Transl Oncol. 2023 May;25(5):1167-1188. doi: 10.1007/s12094-022-03043-y. Epub 2022 Dec 23. Clin Transl Oncol. 2023. PMID: 36562927 Review.
The pharmacological and biological importance of EZH2 signaling in lung cancer.
Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, Zandieh MA, Aboutalebi M, Kakavand A, Rezaei S, Hejazi ES, Saebfar H, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. Entezari M, et al. Among authors: hejazi es. Biomed Pharmacother. 2023 Apr;160:114313. doi: 10.1016/j.biopha.2023.114313. Epub 2023 Feb 3. Biomed Pharmacother. 2023. PMID: 36738498 Free article. Review.
LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions.
Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. Entezari M, et al. Among authors: hejazi es. Biomed Pharmacother. 2022 Oct;154:113609. doi: 10.1016/j.biopha.2022.113609. Epub 2022 Aug 27. Biomed Pharmacother. 2022. PMID: 36037786 Free article. Review.